The Biomarker Copeptin is an important predictor of 90-day mortality and/or re-hospitalization in patients with acute decompensated heart failure. Copeptin levels below 50 pmol/l at the time of admission and an increase of Copeptin levels within the first 72h indicate a significantly increased risk of mortality and readmission.
The results of the MOLITOR-study were presented by Hans-Dirk Düngen, MD PHD of the Charité Berlin and CEO at Scirent at the ESC heart failure meeting 2013, the largest meeting in the field. The ESC 20013 took place from May 25th through May 28th in Lisbon, Portugal. The MOLITOR-Study investigated the concentration of MR-proANP, MR-proADM, Copeptin, NT-proBNP and CT-proET1 in patients with acute decompensation of heart failure (ADHF) during clinical follow-up. The study goal focuses on the ideal time point to measure the previously mentioned biomarkers.